Cutting edge: inhibition of experimental tumor metastasis by dendritic cells pulsed with alpha-galactosylceramide - PubMed (original) (raw)
. 1999 Sep 1;163(5):2387-91.
Affiliations
- PMID: 10452972
Cutting edge: inhibition of experimental tumor metastasis by dendritic cells pulsed with alpha-galactosylceramide
I Toura et al. J Immunol. 1999.
Abstract
A unique lymphoid lineage, Valpha14 NKT cells, bearing an invariant Ag receptor encoded by Valpha14 and Jalpha281 gene segments, play crucial roles in various immune responses, including protective immunity against malignant tumors. A specific ligand of Valpha14 NKT cells is determined to be alpha-galactosylceramide (alpha-GalCer) which is presented by the CD1d molecule. Here, we report that dendritic cells (DCs) pulsed with alpha-GalCer effectively induce potent antitumor cytotoxic activity by specific activation of Valpha14 NKT cells, resulting in the inhibition of tumor metastasis in vivo. Moreover, a complete inhibition of B16 melanoma metastasis in the liver was observed when alpha-GalCer-pulsed DCs were injected even 7 days after transfer of tumor cells to syngeneic mice where small but multiple metastatic nodules were already formed. The potential utility of DCs pulsed with alpha-GalCer for tumor immunotherapy is discussed.
Similar articles
- Innate Valpha14(+) natural killer T cells mature dendritic cells, leading to strong adaptive immunity.
Fujii S, Shimizu K, Hemmi H, Steinman RM. Fujii S, et al. Immunol Rev. 2007 Dec;220:183-98. doi: 10.1111/j.1600-065X.2007.00561.x. Immunol Rev. 2007. PMID: 17979847 Review. - Decreased expressions of CD1d molecule on liver dendritic cells in subcutaneous tumor bearing mice.
Tatsumi T, Takehara T, Yamaguchi S, Sasakawa A, Yamamoto M, Fujita Y, Miyagi T, Ohkawa K, Hayashi N. Tatsumi T, et al. J Hepatol. 2008 Nov;49(5):779-86. doi: 10.1016/j.jhep.2008.06.011. Epub 2008 Jul 2. J Hepatol. 2008. PMID: 18760855 - A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer.
Ishikawa A, Motohashi S, Ishikawa E, Fuchida H, Higashino K, Otsuji M, Iizasa T, Nakayama T, Taniguchi M, Fujisawa T. Ishikawa A, et al. Clin Cancer Res. 2005 Mar 1;11(5):1910-7. doi: 10.1158/1078-0432.CCR-04-1453. Clin Cancer Res. 2005. PMID: 15756017 Clinical Trial. - Enhanced tumor metastasis in response to blockade of the chemokine receptor CXCR6 is overcome by NKT cell activation.
Cullen R, Germanov E, Shimaoka T, Johnston B. Cullen R, et al. J Immunol. 2009 Nov 1;183(9):5807-15. doi: 10.4049/jimmunol.0803520. Epub 2009 Oct 7. J Immunol. 2009. PMID: 19812206 - Role of alpha-galactosylceramide-activated Valpha14 natural killer T cells in the regulation of allergic diseases.
Iwamura C, Nakayama T. Iwamura C, et al. Allergol Int. 2007 Mar;56(1):1-6. doi: 10.2332/allergolint.R-06-136. Epub 2007 Jan 29. Allergol Int. 2007. PMID: 17259803 Review.
Cited by
- Traversing the bench to bedside journey for iNKT cell therapies.
O'Neal J, Mavers M, Jayasinghe RG, DiPersio JF. O'Neal J, et al. Front Immunol. 2024 Aug 7;15:1436968. doi: 10.3389/fimmu.2024.1436968. eCollection 2024. Front Immunol. 2024. PMID: 39170618 Free PMC article. Review. - Fusogenic vesicular stomatitis virus combined with natural killer T cell immunotherapy controls metastatic breast cancer.
Nelson A, McMullen N, Gebremeskel S, De Antueno R, Mackenzie D, Duncan R, Johnston B. Nelson A, et al. Breast Cancer Res. 2024 May 15;26(1):78. doi: 10.1186/s13058-024-01818-5. Breast Cancer Res. 2024. PMID: 38750591 Free PMC article. - Regeneration of invariant natural killer T (iNKT) cells: application of iPSC technology for iNKT cell-targeted tumor immunotherapy.
Aoki T, Motohashi S, Koseki H. Aoki T, et al. Inflamm Regen. 2023 May 12;43(1):27. doi: 10.1186/s41232-023-00275-5. Inflamm Regen. 2023. PMID: 37170375 Free PMC article. Review. - Towards a better understanding of human iNKT cell subpopulations for improved clinical outcomes.
Look A, Burns D, Tews I, Roghanian A, Mansour S. Look A, et al. Front Immunol. 2023 Apr 19;14:1176724. doi: 10.3389/fimmu.2023.1176724. eCollection 2023. Front Immunol. 2023. PMID: 37153585 Free PMC article. Review. - Augmenting Granzyme B-Expressing NK Cells by Invariant NKT Ligand-Loaded APCs in Patients with Postoperative Early Stage Non-Small Cell Lung Cancer: Results of a Randomized Phase II Study.
Iyoda T, Shimizu K, Kawamura M, Shinga J, Watanabe T, Fukunaga K, Mushiroda T, Saka H, Kitagawa C, Shimamatsu SI, Takenoyama M, Suehiro Y, Imai T, Shintani A, Ito S, Fujii SI. Iyoda T, et al. Immunohorizons. 2023 Jan 1;7(1):1-16. doi: 10.4049/immunohorizons.2200091. Immunohorizons. 2023. PMID: 36637516 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Molecular Biology Databases